These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 39164940)

  • 1. p53 Abnormal (Copy Number High) Endometrioid Endometrial Carcinoma Has a Prognosis Indistinguishable From Serous Carcinoma.
    Vaziri Fard E; Imboden S; Rau T; Epstein E; Petta TB; Walia S; Carlson JW
    Int J Gynecol Pathol; 2024 Sep; 43(5):515-526. PubMed ID: 39164940
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecularly Classified Uterine FIGO Grade 3 Endometrioid Carcinomas Show Distinctive Clinical Outcomes But Overlapping Morphologic Features.
    Joehlin-Price A; Van Ziffle J; Hills NK; Ladwig N; Rabban JT; Garg K
    Am J Surg Pathol; 2021 Mar; 45(3):421-429. PubMed ID: 33021522
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular Classification of Grade 3 Endometrioid Endometrial Cancers Identifies Distinct Prognostic Subgroups.
    Bosse T; Nout RA; McAlpine JN; McConechy MK; Britton H; Hussein YR; Gonzalez C; Ganesan R; Steele JC; Harrison BT; Oliva E; Vidal A; Matias-Guiu X; Abu-Rustum NR; Levine DA; Gilks CB; Soslow RA
    Am J Surg Pathol; 2018 May; 42(5):561-568. PubMed ID: 29505428
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinicopathological analysis of endometrial carcinomas harboring somatic POLE exonuclease domain mutations.
    Hussein YR; Weigelt B; Levine DA; Schoolmeester JK; Dao LN; Balzer BL; Liles G; Karlan B; Köbel M; Lee CH; Soslow RA
    Mod Pathol; 2015 Apr; 28(4):505-14. PubMed ID: 25394778
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular Genetics of Endometrial Carcinoma.
    Bell DW; Ellenson LH
    Annu Rev Pathol; 2019 Jan; 14():339-367. PubMed ID: 30332563
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The clinicopathology and survival characteristics of patients with POLE proofreading mutations in endometrial carcinoma: A systematic review and meta-analysis.
    Jumaah AS; Al-Haddad HS; McAllister KA; Yasseen AA
    PLoS One; 2022; 17(2):e0263585. PubMed ID: 35139130
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Are the uterine serous carcinomas underdiagnosed? Histomorphologic and immunohistochemical correlates and clinical follow up in high-grade endometrial carcinomas initially diagnosed as high-grade endometrioid carcinoma.
    Hu S; Hinson JL; Matnani R; Cibull ML; Karabakhtsian RG
    Mod Pathol; 2018 Feb; 31(2):358-364. PubMed ID: 28984301
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Utility of p16 expression for distinction of uterine serous carcinomas from endometrial endometrioid and endocervical adenocarcinomas: immunohistochemical analysis of 201 cases.
    Yemelyanova A; Ji H; Shih IeM; Wang TL; Wu LS; Ronnett BM
    Am J Surg Pathol; 2009 Oct; 33(10):1504-14. PubMed ID: 19623034
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A dualistic model for endometrial carcinogenesis based on immunohistochemical and molecular genetic analyses.
    Lax SF; Kurman RJ
    Verh Dtsch Ges Pathol; 1997; 81():228-32. PubMed ID: 9474874
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mixed endometrial carcinomas with a "low-grade serous"-like component: a clinicopathologic, immunohistochemical, and molecular genetic study.
    Espinosa I; D'Angelo E; Corominas M; Gonzalez A; Prat J
    Hum Pathol; 2018 Jan; 71():65-73. PubMed ID: 29079180
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Polymerase Epsilon Exonuclease Domain Mutations in Ovarian Endometrioid Carcinoma.
    Hoang LN; McConechy MK; Köbel M; Anglesio M; Senz J; Maassen M; Kommoss S; Meng B; Postovit L; Kelemen LE; Staebler A; Brucker S; Krämer B; McAlpine JN; Gilks CB; Huntsman DG; Lee CH
    Int J Gynecol Cancer; 2015 Sep; 25(7):1187-93. PubMed ID: 26166557
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Blinded histopathological characterisation of POLE exonuclease domain-mutant endometrial cancers: sheep in wolf's clothing.
    Van Gool IC; Ubachs JEH; Stelloo E; de Kroon CD; Goeman JJ; Smit VTHBM; Creutzberg CL; Bosse T
    Histopathology; 2018 Jan; 72(2):248-258. PubMed ID: 28795426
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Equivalent Survival of p53 Mutated Endometrial Endometrioid Carcinoma Grade 3 and Endometrial Serous Carcinoma.
    Brett MA; Atenafu EG; Singh N; Ghatage P; Clarke BA; Nelson GS; Bernardini MQ; Köbel M
    Int J Gynecol Pathol; 2021 Mar; 40(2):116-123. PubMed ID: 32265358
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synchronous Endometrial and Ovarian Carcinomas: Pathologic and Molecular Analysis Highlights the Monoclonal Origin of the Lesions.
    Guerriero A; Moro M; Angerilli V; Munari G; Santoro L; Alessandrini L; Favero L; Tasca G; Fassan M; Dei Tos AP
    Int J Gynecol Pathol; 2024 Jul; 43(4):309-315. PubMed ID: 37922918
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical outcomes of patients with POLE mutated endometrioid endometrial cancer.
    Stasenko M; Tunnage I; Ashley CW; Rubinstein MM; Latham AJ; Da Cruz Paula A; Mueller JJ; Leitao MM; Friedman CF; Makker V; Soslow RA; DeLair DF; Hyman DM; Zamarin D; Alektiar KM; Aghajanian CA; Abu-Rustum NR; Weigelt B; Cadoo KA
    Gynecol Oncol; 2020 Jan; 156(1):194-202. PubMed ID: 31757464
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Endometrial carcinoma: 10 years of TCGA (the cancer genome atlas): A critical reappraisal with comments on FIGO 2023 staging.
    Espinosa I; D'Angelo E; Prat J
    Gynecol Oncol; 2024 Jul; 186():94-103. PubMed ID: 38615479
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An NRG Oncology/GOG study of molecular classification for risk prediction in endometrioid endometrial cancer.
    Cosgrove CM; Tritchler DL; Cohn DE; Mutch DG; Rush CM; Lankes HA; Creasman WT; Miller DS; Ramirez NC; Geller MA; Powell MA; Backes FJ; Landrum LM; Timmers C; Suarez AA; Zaino RJ; Pearl ML; DiSilvestro PA; Lele SB; Goodfellow PJ
    Gynecol Oncol; 2018 Jan; 148(1):174-180. PubMed ID: 29132872
    [TBL] [Abstract][Full Text] [Related]  

  • 18. p53, Mismatch Repair Protein, and POLE Abnormalities in Ovarian Clear Cell Carcinoma: An Outcome-based Clinicopathologic Analysis.
    Parra-Herran C; Bassiouny D; Lerner-Ellis J; Olkhov-Mitsel E; Ismiil N; Hogen L; Vicus D; Nofech-Mozes S
    Am J Surg Pathol; 2019 Dec; 43(12):1591-1599. PubMed ID: 31335355
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular-based classification algorithm for endometrial carcinoma categorizes ovarian endometrioid carcinoma into prognostically significant groups.
    Parra-Herran C; Lerner-Ellis J; Xu B; Khalouei S; Bassiouny D; Cesari M; Ismiil N; Nofech-Mozes S
    Mod Pathol; 2017 Dec; 30(12):1748-1759. PubMed ID: 28776572
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of
    Beinse G; Rance B; Just PA; Izac B; Letourneur F; Saidu NEB; Chouzenoux S; Nicco C; Goldwasser F; Batteux F; Durdux C; Chapron C; Pasmant E; Leroy K; Alexandre J; Borghese B
    Int J Gynecol Cancer; 2020 May; 30(5):640-647. PubMed ID: 32169874
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.